<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03901235</url>
  </required_header>
  <id_info>
    <org_study_id>TJT1707P1</org_study_id>
    <nct_id>NCT03901235</nct_id>
  </id_info>
  <brief_title>MSC Intratissular Injection in Crohn Disease Patients</brief_title>
  <acronym>MSC</acronym>
  <official_title>Treatment of Refractory Crohn's Disease Lesions by Local Injection of Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire de Thérapie Cellulaire et Génétique from CHU de Liège</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to assess the efficacy of local injection of MSC on the healing of
      refractory intestinal and perianal lesions in crohn disease. The second co-primary endpoint
      is safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Non-controlled, non-randomized, open label study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with deep ulcer healing</measure>
    <time_frame>Week 12</time_frame>
    <description>Complete deep ulcer healing is defined by the disappearance of the ulcer; partial healing is defined by a decrease in the depth or the diameter of the ulcer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with stricture healing</measure>
    <time_frame>Week 12</time_frame>
    <description>Complete stricture healing is defined by the ability to pass the ileocolonoscope through the stricture; partial healing is defined by the increase in the diameter of the stricture.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with complex perianal fistula healing</measure>
    <time_frame>Week 12</time_frame>
    <description>Complete complex perianal fistula healing is defined by the complete closure of the external fistula opening, no drainage upon gentle pressure, no abscess. And by looking at the size of the fistulous track, presence of collection, and gadolinium enhancement by MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by the incidence of treatment-emergent adverse events during the study period</measure>
    <time_frame>from week 0 to week 48</time_frame>
    <description>Assessment of the incidence of adverse and serious adverse events over the 48 weeks study period. Toxicity grade of adverse events is determined using the Common Terminology Criteria for Adverse Events (version 4.0). Relationship to the therapeutic procedure will systematically be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of clinical disease activity index</measure>
    <time_frame>week 0, 12 and 48</time_frame>
    <description>Assess disease activity in Crohn's disease over 7 days using the Crohn's disease activity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Short health scale (quality of life)</measure>
    <time_frame>week 0, 12 and 48</time_frame>
    <description>min : 0 - max : 10 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the Lemann Index (measuring cumulated intestinal damage in Crohn's disease)</measure>
    <time_frame>week 0, 12 and 48</time_frame>
    <description>which incorporates clinical, surgical, endoscopic, and imaging findings from all segments of the digestive tract into one composite score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the &quot; Group of Therapeutic Study of Inflammatory Disorders of the Digestive Tube&quot; obstructive score for Crohn Disease strictures</measure>
    <time_frame>weeks 0, 12 and 48</time_frame>
    <description>Grade : from 0 to higher value 6</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Efficacy and Safety</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stromal Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stromal Cells</intervention_name>
    <description>Suspension of mesenchymal stromal cells for intratissular injection</description>
    <arm_group_label>Mesenchymal Stromal Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years of age

          -  Signing the informed consent

          -  Diagnosis of Crohn Disease for more than 6 months

          -  Presence of at least one Crohn Disease lesion refractory to conventional therapies
             (azathioprine, 6-mercaptopurine or methotrexate) and to biologic treatments
             (anti-Tumor Necrosis Factor therapies, vedolizumab, or ustekinumab).

          -  Refractory lesion defined by (1) a stricture with a length of 2 to 5cm of the colon or
             the ileum accessible by ileocolonoscopy (i.e. a lesion identified during a colonoscopy
             with a lumen narrowing non passable by the colonoscope), (2) unhealed deep ulcer of
             the colon or the ileum accessible to ileocolonoscopy, or (3) actively draining
             perianal fistula(s).

          -  Twenty patients with stricture(s), 20 patients with unhealed deep ulcer(s), and 20
             patients with an actively draining perianal fistula(s) will be included

        Exclusion Criteria:

          -  Indication for immediate luminal surgery

          -  Intestinal obstruction

          -  Intra-abdominal fistulas or abscess

          -  Intestinal/colonic stricture or deep unhealed ulcer not accessible to ileocolonoscopy

          -  Undrained peri-anal abscess

          -  Pregnant women or planning pregnancy within one year

          -  Positive stool culture/toxin for clostridium difficile pathogen or other pathogens

          -  Renal failure (anuria, serious fluid overload, Glomerular Filtration Rate &lt; 30 ml/min,
             dialysis) or hepatic failure (Fulminant liver failure, cirrhosis of the liver with
             evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of
             bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic
             dysfunction evinced by prolongation of the prothrombin time, ascites related to portal
             hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral
             hepatitis with total serum bilirubin &gt;3 mg/dL)

          -  documented human immunodeficiency virus infection; active hepatitis B, C, or
             tuberculosis

          -  an opportunistic infection within 6 months before screening or a serious infection in
             the previous 3 months

          -  malignancy within the past 5 years; or a history of lymphoproliferative disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edouard Louis, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Liège</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edouard Louis, Prof</last_name>
    <phone>043667256</phone>
    <phone_ext>0032</phone_ext>
    <email>edouard.louis@uliege.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chantal Lechanteur</last_name>
    <phone>043668390</phone>
    <phone_ext>0032</phone_ext>
    <email>c.lechanteur@chuliege.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Louis, Prof</last_name>
      <phone>043667256</phone>
      <phone_ext>043667256</phone_ext>
      <email>edouard.louis@uliege.be</email>
    </contact>
    <contact_backup>
      <last_name>Layla Boutaffala</last_name>
      <phone>043668065</phone>
      <phone_ext>0032</phone_ext>
      <email>lboutaffala@chuliege.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Edouard Louis</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

